Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - An extended haplotype of genetic variants increases risk in indinavir treatment
Keywords: سندرم گیلبرت; Protease inhibitor; Gilbert's syndrome; Pharmacogenetics; UGT1A1; Hyperbilirubinemia; Irinotecan; Indinavir;